Aprea Therapeutics APRE 深 沪
等待开盘 08-14 09:30:00 美东时间
0.671
-0.012
-1.76%
华盛通- 最 高0.6816
- 今 开0.671
- 成交量 2.13万股
- 最 低 0.6563
- 昨 收 0.683
- 总市值 830.88万
- 52周最高 1.69
- 市盈率 静 --
- 换手率 0.17%
- 52周最低 0.548
- 委 比 92.31%
- 总股本 1238.28万
- 历史最高 1062.20
- 量 比 0.74
- 振 幅 3.70%
- 历史最低 0.548
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
今天 11:51
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.
08-13 20:55
Aprea Therapeutics advances APR-1051 oncology pipeline progress
Aprea Therapeutics ( ($APRE) ) has shared an announcement. On August 12, 2026, ...
08-12 20:58
Aprea Therapeutics Q2 EPS $(0.07) Beats $(0.23) Estimate
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 86.79 percent increase over losses of $(0.53) per share from the same period last year.
08-12 20:32
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Aprea Therapeutics plans to report the next clinical data update for its Phase 1 ACESOT-1051 trial of APR-1051, an oral WEE1 inhibitor, at a medical meeting in Q4 2026. Enrollment is accelerating, with 6-10 patients expected per month by year-end. The company aims to expand APR-1051's development into uterine serous carcinoma, platinum-resistant ovarian cancer, and combination therapies for HPV-positive head and neck cancer and colorectal cancer....
07-30 12:00
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in June 2026
Short interest data from late June 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in speculative biotech plays like Rec...
07-01 22:20
Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
06-01 20:08
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Aprea Therapeutics presented early results from the ACESOT-1051 Phase 1 study of APR-1051, a WEE1 inhibitor, at the 2026 ASCO meeting. Key highlights include partial responses and stable disease in multiple tumor types, manageable tolerability, and ongoing patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer. Dose escalation is expected to complete in Q2 2027. APR-1051 demonstrates promising safety and efficacy pr...
06-01 12:00
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $7 to $6.
05-14 21:17
